Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Merck (MRK) shares fell 2% in premarket trading on Thursday even after topping Wall Street expectations with its Q3 results, ...

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

Thinking about picking up some Merck KGaA shares, but wondering if the current price tag does the business justice? You're not alone. Value hunters and long-term investors keep asking the same ...

The company will begin its domestic investment by starting construction on a $3 billion pharmaceutical manufacturing site in ...

Merck & Co beat third-quarter (3Q) sales expectations on strong results from its pneumonia vaccine as the company works to ...

Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug ...

The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...

Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life ...

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...